Pharmaceutical & Biopharmaceutical Market was the largest of Agilent Technologies, Inc.’s 6 reported lines in fiscal 2025, at $2.51B — 36% of $6.95B.
| End Markets | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Pharmaceutical & Biopharmaceutical Market | $2.52B | $2.43B | $2.24B | $2.51B | |||
| Chemical & Advanced Materials Market | $1.52B | $1.54B | $1.50B | $1.56B | |||
| Chemical & Energy Market | — | — | — | — | |||
| Diagnostics & Clinical Market | $963.00M | $966.00M | $964.00M | $1.03B | |||
| Environmental & Forensics Market | $656.00M | $662.00M | $650.00M | $674.00M | |||
| Food Market | $617.00M | $628.00M | $592.00M | $637.00M | |||
| Academia & Government Market | $576.00M | $601.00M | $567.00M | $540.00M | |||
| Total | $6.85B | $6.83B | $6.51B | $6.95B |
In fiscal 2025, which ended October 31, 2025, the 6 regions Agilent Technologies, Inc. reported in this breakdown added up to $6.95B. That was up 6.7% from $6.51B in fiscal 2024. Pharmaceutical & Biopharmaceutical Market was the largest region, at $2.51B or 36.1% of the total, followed by Chemical & Advanced Materials Market ($1.56B, 22.5%) and Diagnostics & Clinical Market ($1.03B, 14.8%). Together, the two largest regions made up 58.5% of this total.
Compared with fiscal 2024, Pharmaceutical & Biopharmaceutical Market grew the fastest, rising 11.8% to $2.51B. Academia & Government Market fell the most, down 4.8% to $540.00M. Over fiscal 2022 to 2025, revenue across these regions went from $6.85B to $6.95B, a compound annual growth rate of 0.5%. Pharmaceutical & Biopharmaceutical Market's share of the total fell from 36.7% to 36.1% over the same years.
The table also keeps 1 region that Agilent Technologies, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 1 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2019 to 2025, as reported in Agilent Technologies, Inc.'s annual filings.
Life Sciences & Diagnostics Markets was the largest of Agilent Technologies, Inc.’s 3 reported lines in fiscal 2025, at $1.34B — 44% of $3.05B.
| Business Segments | FY 2009 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Life Sciences & Applied Markets | $1.68B | — | — | — | ||||||||||
| Electronic Measurement | — | — | — | — | ||||||||||
| Life Sciences & Diagnostics Markets | — | $1.33B | $1.16B | $1.34B | ||||||||||
| Life Sciences | — | — | — | — | ||||||||||
| Agilent Crosslab | $567.00M | $1.00B | $1.05B | $1.10B | ||||||||||
| Diagnostics & Genomics | $1.01B | — | — | — | ||||||||||
| Chemical Analysis | — | — | — | — | ||||||||||
| Applied Markets | — | $677.00M | $623.00M | $614.00M | ||||||||||
| Total | $3.25B | $3.01B | $2.83B | $3.05B |
In fiscal 2025, which ended October 31, 2025, the 3 segments Agilent Technologies, Inc. reported in this breakdown added up to $3.05B. That is less than the $6.95B in its breakdown by region, so these segments do not account for all of its revenue that year. Life Sciences & Diagnostics Markets was the largest segment, at $1.34B or 43.9% of the total, followed by Agilent Crosslab ($1.10B, 35.9%) and Applied Markets ($614.00M, 20.2%). Together, the two largest segments made up 79.8% of this total.
Compared with fiscal 2024, Life Sciences & Diagnostics Markets grew the fastest, rising 15.6% to $1.34B. Applied Markets fell the most, down 1.4% to $614.00M.
Life Sciences & Diagnostics Markets (fiscal 2023) and Applied Markets (fiscal 2023) were first reported as separate segments during this period. The table also keeps 5 segments that Agilent Technologies, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 5 discontinued" beneath the table to see them. This breakdown covers 14 fiscal years between 2009 and 2025, as reported in Agilent Technologies, Inc.'s annual filings.
Products was the largest of Agilent Technologies, Inc.’s 2 reported lines in fiscal 2025, at $4.94B — 71% of $6.95B.
| Product and Service | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Products | $5.19B | $5.05B | $4.67B | $4.94B | |||||||||
| Instrumentation | — | — | — | — | |||||||||
| Services & Other | $1.66B | $1.78B | $1.84B | $2.00B | |||||||||
| Analytical Lab Services | — | — | — | — | |||||||||
| Diagnostics & Genomics Solutions | — | — | — | — | |||||||||
| Analytical Lab Consumables | — | — | — | — | |||||||||
| Informatics & Other | — | — | — | — | |||||||||
| Total | $6.85B | $6.83B | $6.51B | $6.95B |
In fiscal 2025, which ended October 31, 2025, the 2 revenue lines Agilent Technologies, Inc. reported in this breakdown added up to $6.95B. That was up 6.7% from $6.51B in fiscal 2024. Products was the largest revenue line, at $4.94B or 71.2% of the total, followed by Services & Other ($2.00B, 28.8%).
Compared with fiscal 2024, Services & Other grew the fastest, rising 9.0% to $2.00B. Over fiscal 2022 to 2025, revenue across these revenue lines went from $6.85B to $6.95B, a compound annual growth rate of 0.5%. Products' share of the total fell from 75.7% to 71.2% over the same years.
The table also keeps 5 revenue lines that Agilent Technologies, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 5 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2013 to 2025, as reported in Agilent Technologies, Inc.'s annual filings.
Agilent Technologies, Inc. (A) breaks its revenue down by region, segment and revenue line. In fiscal 2025, its largest region was Pharmaceutical & Biopharmaceutical Market, with $2.51B or 36.1% of the total, followed by Chemical & Advanced Materials Market at $1.56B (22.5%).
Pharmaceutical & Biopharmaceutical Market was Agilent Technologies, Inc.'s largest region in fiscal 2025, with $2.51B in revenue, 36.1% of the $6.95B reported across its 6 regions.
Life Sciences & Diagnostics Markets was Agilent Technologies, Inc.'s largest segment in fiscal 2025, with $1.34B in revenue, 43.9% of the $3.05B reported across its 3 segments.
Products was Agilent Technologies, Inc.'s largest revenue line in fiscal 2025, with $4.94B in revenue, 71.2% of the $6.95B reported across its 2 revenue lines.
Of the Agilent Technologies, Inc. regions reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Pharmaceutical & Biopharmaceutical Market grew the fastest, rising 11.8% from $2.24B to $2.51B.
Every figure is taken from Agilent Technologies, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by region covers fiscal 2019 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.